SCHEMBL261957

SCHEMBL261957

COc1nc2ccccc2cc1NC(=O)Nc1cc2ccccc2nc1OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.49
SMN1; SMN2 Q16637 4/20 0.49
RAB9A P51151 2/20 0.48
IGF1R P08069 3/20 0.46
MAPK1 P28482 1/20 0.45
BTK Q06187 1/20 0.45
KDM4E B2RXH2 4/20 0.44
ALDH1A1 P00352 3/20 0.43
HPGD P15428 3/20 0.43
HSD17B10 Q99714 2/20 0.43
KMT2A Q03164 2/20 0.43
NPC1 O15118 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
RCE1 Q9Y256 1/20 0.43
GAA P10253 1/20 0.43
MEN1 O00255 1/20 0.43
POLB P06746 2/20 0.43
ADORA3 P0DMS8 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL938402 0.83 RAF1 (0.58) MAPTSMN1; SMN2IGF1RMAPK1ALDH1A1
SCHEMBL6964824 0.83 ALDH1A1 (0.51) MAPTSMN1; SMN2RAB9AKDM4EALDH1A1
SCHEMBL6956521 0.82 MAPT (0.42) MAPTSMN1; SMN2RAB9ABTKKDM4E
SCHEMBL8549283 0.82 MAPT (0.56) MAPTSMN1; SMN2RAB9AMAPK1ALDH1A1
SCHEMBL22641580 0.80 TLR8 (0.46) MAPTSMN1; SMN2RAB9ABTKKDM4E
SCHEMBL846695 0.80 TRPV1 (0.58) MAPTSMN1; SMN2RAB9AKDM4EALDH1A1
SCHEMBL939310 0.80 ALDH1A1 (0.46) MAPTSMN1; SMN2MAPK1KDM4EALDH1A1
SCHEMBL12719565 0.78 MEN1 (0.54) SMN1; SMN2IGF1RHPGDKMT2AMEN1
SCHEMBL4185779 0.78 RAF1 (0.58) RAB9AIGF1RKMT2ANPC1MEN1
SCHEMBL6956523 0.77 RAB9A (0.40) MAPTSMN1; SMN2RAB9ABTKKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2386545-A1 Heteroaryl ureas containing nitrogen hetero-atoms as P38 kinase inhibitors Bayer Healthcare LLC (US) 2011-11-16 EP disclosed
EP-1379507-B1 HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS p38 KINASE INHIBITORS BAYER HEALTHCARE LLC (US) 2011-08-17 EP disclosed
US-20080194580-A1 Inhibition Of Raf Kinase Using Quinolyl, Isoquinolyl Or Pyridyl Ureas BAYER HEALTHCARE LLC 2008-08-14 US disclosed
US-20080194580-A1 Inhibition Of Raf Kinase Using Quinolyl, Isoquinolyl Or Pyridyl Ureas BAYER HEALTHCARE LLC 2008-08-14 US disclosed
US-7371763-B2 Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas BAYER PHARMACEUTICALS CORPORATION (US) 2008-05-13 US disclosed
US-7371763-B2 Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas BAYER PHARMACEUTICALS CORPORATION (US) 2008-05-13 US disclosed
EP-1379505-B1 INHIBITION OF RAF KINASE USING QUINOLYL, ISOQUINOLYL OR PYRIDYL UREAS BAYER PHARMACEUTICALS CORP (US) 2007-02-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194580-A1 Inhibition Of Raf Kinase Using Quinolyl, Isoquinolyl Or Pyridyl Ureas BRAF, RAF1, ARAF MAPT 908/4885SMN1; SMN2 4613/4885RAB9A 558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.